A Skeptic’s Guide to Ozempic and Other GLP-1 Agonists
Skeptic • • health
Key Points:
- The SKEPDOC column, founded by Harriet Hall, MD, will be led by William Meller, MD starting in 2026, focusing on evolutionary medicine to guide human health insights.
- GLP-1 receptor agonists, derived from Gila monster venom, have revolutionized treatment for obesity and Type 2 diabetes by improving glycemic control, promoting significant weight loss, and reducing cardiovascular risks.
- Despite their efficacy, GLP-1 agonists carry notable side effects such as gastrointestinal distress, potential pancreatitis risk, muscle loss, and safety concerns related to surgery and mental health, requiring careful patient monitoring.
- New developments include oral GLP-1 agonists like orforglipron, which offer convenience without injections but
